In a matched cohort of 103 BC patients, Jones et al. found post-therapy Ki67 to be the only significant independent prognostic factor for DFS in multivariate analysis (p < 0.001), and the strongest prognostic factor for OS (p < 0.001) [49]. This evidence concerns the gene MKI67 and breast cancer.